Get to know our clinical trials

Clinical trial of GFH925 in combination with cetuximab in patients with previously untreated advanced stage KRAS G12C mutated NSCLC

THE OBJECTIVE OF THIS STUDY IS TO EXAMINE AN INVESTIGATIONAL DRUG, GFH925, WHEN USED IN COMBINATION WITH AN ANTINEOPLASTIC CALLED "CETUXIMAB", IN PEOPLE WITH A PARTICULAR TYPE OF NSCLC, CALLED "NSCLC WITH KRAS G12C MUTATION". THE KRAS G12C MUTATION IS A TYPE OF MUTATION OF A GROUP OF GENES THAT CONTROL CELL GROWTH AND DIVISION. GENES ARE SEGMENTS OF DEOXYRIBONUCLEIC ACID (DNA), WHICH IS PRESENT IN MOST CELLS. GENES DECIDE THE FUNCTION AND ACTIONS OF THE CELL. WHEN MUTATED, THE GENE CAN CAUSE NORMAL CELLS TO BECOME CANCEROUS AND GROW UNCONTROLLABLY. TUMORS WITH KRAS MUTATIONS HAVE BEEN SHOWN TO BE UNRESPONSIVE TO CERTAIN TYPES OF LUNG CANCER TREATMENT. THE INVESTIGATIONAL DRUG IS DESIGNED TO STOP THE GROWTH OF TUMOR CELLS WITH THE KRAS G12C MUTATION, WHICH COULD DESTROY ONLY CANCER CELLS AND PRESERVE NORMAL CELLS. THIS TRIAL WILL EXAMINE THE TRIAL MEDICATION TO TEST: WHAT SIDE EFFECTS THE TRIAL MEDICATION MAY CAUSE (REFERRED TO AS "SAFETY"); HOW THE TRIAL MEDICATION IS HANDLED BY THE BODY (REFERRED TO AS "TOLERABILITY"); HOW THE TRIAL MEDICATION WORKS (REFERRED TO AS "EFFICACY"); AND HOW THE TRIAL MEDICATION IS ABSORBED, DISTRIBUTED AND EXCRETED BY THE BODY (REFERRED TO AS "PHARMACOKINETICS" OR "PK").

Status
In recruitment
headquarters
Pamplona/Madrid

Technical Summary

  • PHASE IB/II, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY/TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF GFH925 IN COMBINATION WITH CETUXIMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED-STAGE KRAS G12C-MUTATED NSCLC WITH KRAS G12C MUTATION
  • Code EudraCT: 2022-501451-87-00
  • Protocol number: GFH925X0201
  • Promoter: Zhejiang GenFleet Therapeutics Co., Ltd.

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.